M&A / Deals Merck Chopped $1B Off Terns’ Offer After Seeing Updated Leukemia Data BioSpaceAnother bidder, which remains unidentified, dropped out of the bidding process.M&A / DealsHematologyRead full story pharminent April 8, 2026 (Last updated: April 8, 2026) BioSpace Another bidder, which remains unidentified, dropped out of the bidding process. M&A / DealsHematologyRead full story Post navigation Previous: List Price Reductions Will Deflate the Gross-to-Net Bubble-and Threaten Pharmacy and 340B Profits from IRA-Negotiated Drugs (rerun)Next: Insmed Scraps Skin Plans for Lung Disease Drug as Competitors Make Headway Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
